Managing hypertension during the COVID-19 pandemic

J Hum Hypertens. 2020 Jun;34(6):415-417. doi: 10.1038/s41371-020-0356-y. Epub 2020 May 14.

Authors

Sunil K Nadar¹, Muzahir H Tayebjee², Michael Stowasser³, James Brian Byrd⁴

Affiliations

¹ Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman. sunilnadar@gmail.com.
² Department of Cardiology, Leeds teaching hospital, NHS trust, Leeds, UK.
³ Endocrine Hypertension research center, University of Queensland, Princess Alexandra hospital, Brisbane, Australia.
⁴ Department of Internal Medicine, University of Michigan Medical Schooll, Ann Arbor, MI, USA.

No abstract available

Publication types

Editorial

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Betacoronavirus*
COVID-19
Coronavirus Infections / epidemiology*
Humans
Hypertension / drug therapy*
Pandemics
Pneumonia, Viral / epidemiology*
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors